Key factors
sym | BNTX |
exch | US |
MCap | 20.76B |
Beta | 0.228 |
PE Ratio | 21.17 |
EPS | 4.07 |
Div date | 2022-06-02 |
Yesterday
sym | BNTX |
exch | US |
close | 88.09 |
50 Day MA | 91.43 |
200 Day MA | 101.50 |
52 Week High | 125.83 |
52 Week Low | 85.21 |
Target Price | 118.2 |
Market Cap Mln | 20766 |
Share statistics
Shares Outstanding | 240.99M |
Shares Float | 88.96M |
Percent Institutions | 18.33 |
PercentInsiders | 62.83 |
SharesShort | 3076.81K |
Short Ratio | 4.33 |
Shares Short Prior Month | 3082.2K |
Short Percent | 6.419 |
Income
Revenue TTM | 3.819B |
Revenue Per Share TTM | 15.87 |
Quarterly Revenue Growth YOY | -65.3 |
Gross Profit TTM | 16.06B |
EBITDA | 1.107B |
Diluted Eps TTM | 4.07 |
Quarterly Earnings Growth YOY | -79.5 |
earning
Operating Margin TTM | 0.4 |
PEGRatio | 0.044 |
Trailing PE | 21.17 |
EPS Estimate Current Quarter | 2.63 |
EPS Estimate Current Year | -1.62 |
EPS Estimate Next Quarter | -0.43 |
EPS Estimate Next Year | -1.38 |
Earnings Share | 4.07 |
Dividend
Dividend Date | 2022-06-17 |
Last Split Date | 0000-00-00 |
business
Enterprise Value Ebitda | 3.057 |
Enterprise Value Revenue | 0.870 |
Book Value /share | 85.16 |
Price Book MRQ | 0.958 |
Price Sales TTM | 5.457 |
ProfitMargin | 0.243 |
ReturnOnAssetsTTM | 0.026 |
ReturnOnEquityTTM | 0.046 |
Sector
Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
Gic Industry | Biotechnology |
Gic Sector | Health Care |
Gic Sub Industry | Biotechnology |
Industry | Biotechnology |
Sector | Healthcare |
Codes
ISIN | US09075V1026 |
Code | BNTX |
CUSIP | 09075V102 |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NASDAQ |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2024-04-19 |
Home Category | ADR |
info
Fiscal Year End | December |
ForwardPE | 7.037 |
Full Time Employees | 6133.0 |
IPODate | 2019-10-10 |
MostRecent Quarter | 2023-12-31 |
Contact
Name | BioNTech SE |
Address | An der Goldgrube 12, Mainz, Germany, 55131 |
Country Name | USA |
Phone | 49 6131 9084 0 |
Web URL | https://www.biontech.de |
Logo URL | /img/logos/US/BNTX.png |
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.